Are there any serious risks associated with GLP-1 medications
When food lingers in the stomach and intestines longer than usual, it gives bacteria more time to break it down
This makes retatrutide the first triple-receptor agonist to reach late-stage clinical trials, representing the next step in the evolution of incretin-based metabolic research compounds
Angiogenesis and inflammation in the retinopathy risk of insulin and semaglutide - a review
BPC-157 and the Difference Between an Evidence Gap and a Cover-Up: What the entire human evidence base actually looks like, and the questions to ask next
What this means in practice: At PulsePropel Biotech, we are exploring how integrating yeast-based supplementation can complement nutrition strategies, whether in supporting populations with higher micronutrient needs, enhancing gut microbiome resilience, or optimizing general wellness